AZEVAN PHARMACEUTICALS INC

Address

116 RESEARCH DR
BETHLEHEM, PA, 18015-4734

Information

DUNS: 604182118
# of Employees: 7

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Tolerability of SRX246 in Huntington's Disease Patients

    Amount: $3,329,539.00

    DESCRIPTION provided by applicant Huntingtonandapos s Disease HD is an inherited disease that results from expansion of a trinucleotide CAG cytosine adenine guanine repeat that encodes a poly ...

    SBIRPhase I2016Department of Health and Human Services
  2. Tolerability of SRX246 in Huntington's Disease Patients

    Amount: $3,607,743.00

    DESCRIPTION provided by applicant Huntingtonandapos s Disease HD is an inherited disease that results from expansion of a trinucleotide CAG cytosine adenine guanine repeat that encodes a poly ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  3. Screening New Therapeutics for the Treatment of Post Traumatic Stress Disorder

    Amount: $141,071.00

    DESCRIPTION (provided by applicant): Project Summary/Abstract Post-traumatic Stress Disorder (PTSD) is recognized by the NIMH, the Department of Defense, and the Veterans' Administration as ...

    STTRPhase I2011Department of Health and Human Services
  4. New Drugs for Stress-related Affective Illness

    Amount: $1,794,075.00

    DESCRIPTION (provided by applicant): Vasopressin (AVP) antagonists represent a novel therapeutic class for the treatment of depression. The potential utility of these compounds has emerged from observ ...

    SBIRPhase II2011Department of Health and Human Services
  5. New Drugs for Stress-related Affective Illness

    Amount: $349,195.00

    DESCRIPTION (provided by applicant): Vasopressin (AVP) antagonists represent a novel therapeutic class for the treatment of depression. The potential utility of these compounds has emerged from observ ...

    SBIRPhase I2010Department of Health and Human Services
  6. A Potential New Drug for Depression

    Amount: $226,385.00

    DESCRIPTION (provided by applicant): A Potential New Drug for Depression, an active SBIR Phase IIa award. The requested funds will allow additional characterization studies of three newly discovered ...

    SBIRPhase II2009Department of Health and Human Services
  7. TREATING SELF-ABUSE IN AUTISM AND MENTAL RETARDATION

    Amount: $0.00

    Serenix Pharmaceuticals LLC (SPL) will develop drugs to treat impulsivity, violence and self-injurious behavior in patients with autism, Tourette's syndrome, and mental retardation. These drugs, terme ...

    STTRPhase I2002Department of Health and Human Services
  8. A NEW DRUG FOR DEPRESSION

    Amount: $100,000.00

    Long Term Goals: Serenix Pharmaceuticals (SP) will develop drugs for the treatment of CNS disorders. Strategy: SP acquired a series of vasopressin receptor antagonists from Eli Lilly and Company and h ...

    SBIRPhase I2002Department of Health and Human Services
  9. TREATING SELF-ABUSE IN AUTISM AND MENTAL RETARDATION

    Amount: $498,684.00

    Serenix Pharmaceuticals LLC (SPL) will develop drugs to treat impulsivity, violence and self-injurious behavior in patients with autism, Tourette's syndrome, and mental retardation. These drugs, terme ...

    STTRPhase II2002Department of Health and Human Services
  10. N/A

    Amount: $100,000.00

    N/A

    STTRPhase I2000Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government